Modulation of behavior and cortical motor activity in healthy subjects by a chronic administration of a serotonin enhancer

UNLABELLED SSRIs are postulated to modulate motor behavior. A single dose of selective serotoninergic reuptake inhibitors (SSRIs) like fluoxetine, paroxetine, or fluvoxamine, has been shown to improve motor performance and efficiency of information processing for simple sensorimotor tasks in healthy subjects. At a cortical level, a single dose of SSRI was shown to induce a hyperactivation of the primary sensorimotor cortex (S1M1) involved in the movement (Loubinoux, I., Boulanouar, K., Ranjeva, J. P., Carel, C., Berry, I., Rascol, O., Celsis, P., and Chollet, F., 1999. Cerebral functional magnetic resonance imaging activation modulated by a single dose of the monoamine neurotransmission enhancers fluoxetine and fenozolone during hand sensorimotor tasks. J. Cereb. Blood Flow Metab. 19 1365--1375, Loubinoux, I., Pariente, J., Boulanouar, K., Carel, C., Manelfe, C., Rascol, O., Celsis, P., and Chollet, F., 2002. A Single Dose of Serotonin Neurotransmission Agonist Paroxetine Enhances Motor Output. A double-blind, placebo-controlled, fMRI study in healthy subjects. NeuroImage 15 26--36). Since SSRIs are usually given for several weeks, we assessed the behavioral and cerebral effects of a one-month chronic administration of paroxetine on a larger group. In a double-blind, placebo controlled and crossover study, 19 subjects received daily 20 mg paroxetine or placebo, respectively, over a period of 30 days separated by a wash-out period of 3 months. After each period, the subjects underwent an fMRI (active or passive movement, dexterity task, sensory discrimination task) and a behavioral evaluation. Concurrently, a TMS (transcranial magnetic stimulation) study was conducted (Gerdelat-Mas, A., Loubinoux, I., Tombari, D., Rascol, O., Chollet, F., Simonetta-Moreau, M., 2005. Chronic administration of selective serotonin re-uptake inhibitor (SSRI) paroxetine modulates human motor cortex excitability in healthy subjects. NeuroImage 27,314--322). RESULTS On the one hand, paroxetine improved motor performances at the finger tapping test (P=0.02) without affecting choice reaction time, strength and dexterity significantly. Subjects were also faster in processing the spatial incongruency between a stimulus and the motor response (P=0.04). In order to differentiate behavioral components, a principal component analysis was performed on all motor tests, and several characteristics were differentiated: strength, speed, skill, attention, and motor response coding. Paroxetine would improve the efficiency of motor response coding (MANOVA on the factors; factor 3, P=0.01). On the other hand, the chronic administration induced a significant hypoactivation of S1M1 whatever the task: motor or sensory, simple or complex (random effect analysis, P<0.05). The hypoactivation correlated with the improvement of performances at the finger tapping test (P<0.05) suggesting more efficiency in cerebral motor processing. CONCLUSIONS Our results showed a clear modulation of sensory and motor cerebral activation after a chronic paroxetine administration. An improvement in both behavior and cerebral efficiency was suggested. It could be hypothesized that monoamines, by an unspecific effect, may tune the response of pyramidal neurons to optimize performances.

[1]  John L. Musachio,et al.  Positron emission tomography of 5-HT reuptake sites in the human brain with C-11 McN5652 extraction of characteristic images by artificial neural network analysis , 1995, Behavioural Brain Research.

[2]  A. Gjedde,et al.  Quantitative PET analysis of regional cerebral blood flow and glucose and oxygen metabolism in response to fenfluramine in living porcine brain , 1998, Journal of Neuroscience Methods.

[3]  F. Chollet,et al.  A Single Dose of the Serotonin Neurotransmission Agonist Paroxetine Enhances Motor Output: Double-Blind, Placebo-Controlled, fMRI Study in Healthy Subjects , 2002, NeuroImage.

[4]  J. O'hanlon,et al.  Acute and subchronic effects of paroxetine 20 and 40 mg on actual driving, psychomotor performance and subjective assessments in healthy volunteers , 1995, European Neuropsychopharmacology.

[5]  C. Cotman,et al.  Exercise, Antidepressant Medications, and Enhanced Brain Derived Neurotrophic Factor Expression , 1999, Neuropsychopharmacology.

[6]  F. Artigas,et al.  Chronic treatment with fluvoxamine increases extracellular serotonin in frontal cortex but not in raphe nuclei , 1993, Synapse.

[7]  S. Schacher,et al.  Rapid bidirectional modulation of mRNA expression and export accompany long-term facilitation and depression of Aplysia synapses. , 2001, Journal of neurobiology.

[8]  M. Wilson,et al.  The organization of serotonergic projections to cerebral cortex in primates: Retrograde transport studies , 1991, Neuroscience.

[9]  I. Engberg,et al.  The modulation of excitatory amino acid responses by serotonin in the cat neocortexin vitro , 1987, Cellular and Molecular Neurobiology.

[10]  H N Wagner,et al.  Positron Emission Tomography of 5-HT Transporter Sites in the Baboon Brain with [11C]McN5652 , 1995, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[11]  A. Deutch,et al.  Serotonin 5‐HT2A receptors are expressed on pyramidal cells and interneurons in the rat cortex , 1997, Synapse.

[12]  M. Tarnopolsky,et al.  Selective serotonin reuptake inhibitors: Their effect on high-intensity exercise performance. , 2001, Archives of physical medicine and rehabilitation.

[13]  François Chollet,et al.  Chronic administration of selective serotonin reuptake inhibitor (SSRI) paroxetine modulates human motor cortex excitability in healthy subjects , 2005, NeuroImage.

[14]  H. T. Chen,et al.  Quantitative autoradiography of 3H-paroxetine binding sites in rat brain. , 1992, Journal of pharmacological and toxicological methods.

[15]  J. Reynolds,et al.  The effects of serotonin on N-methyl-d-aspartate and synaptically evoked depolarizations in rat neocortical neurons , 1988, Brain Research.

[16]  B. Jacobs,et al.  Serotonin and motor activity , 1997, Current Opinion in Neurobiology.

[17]  Fluoxetine effects on cerebral glucose metabolism. , 1994, Neuroreport.

[18]  W. Riedel,et al.  Tryptophan depletion in normal volunteers produces selective impairment in memory consolidation , 1999, Psychopharmacology.

[19]  T. Rammsayer,et al.  Effects of changes in brain 5-HT activity on indicators of cortical arousal. , 1988, International clinical psychopharmacology.

[20]  J. Kenemans,et al.  Differential effects of amitriptyline, nefazodone and paroxetine on performance and brain indices of visual selective attention and working memory , 2002, Psychopharmacology.

[21]  Stroke Therapy Academic Industry Roundtable Recommendations for standards regarding preclinical neuroprotective and restorative drug development. , 1999, Stroke.

[22]  C. Nemeroff Paroxetine: An Overview of the Efficacy and Safety of a New Selective Serotonin Reuptake Inhibitor in the Treatment of Depression , 1993, Journal of clinical psychopharmacology.

[23]  C. Davidson,et al.  Contrasting effects of chronic paroxetine on 5‐HT1A control of dorsal raphe cell firing and 5‐HT release , 1998, Neuroreport.

[24]  François Chollet,et al.  A longitudinal fMRI study: in recovering and then in clinically stable sub-cortical stroke patients , 2004, NeuroImage.

[25]  G. Aghajanian,et al.  Excitatory responses to serotonin (5‐HT) in neurons of the rat piriform cortex: Evidence for mediation by 5‐HT1C receptors in pyramidal cells and 5‐HT2 receptors in interneurons , 1991, Synapse.

[26]  I. Hindmarch The behavioural toxicity of the selective serotonin reuptake inhibitors , 1995, International clinical psychopharmacology.

[27]  I. Hindmarch,et al.  A placebo controlled investigation into the effects of paroxetine and mirtazapine on measures related to car driving performance , 2003, Human psychopharmacology.

[28]  Sylvain Houle,et al.  Modulation of cortical neuronal activity by a serotonergic agent: a PET study in humans , 1994, Brain Research.

[29]  E. Kandel,et al.  A novel function for serotonin-mediated short-term facilitation in aplysia: conversion of a transient, cell-wide homosynaptic hebbian plasticity into a persistent, protein synthesis-independent synapse-specific enhancement. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[30]  L. Hertz Autonomic control of neuronal-astrocytic interactions, regulating metabolic activities, and ion fluxes in the CNS , 1992, Brain Research Bulletin.

[31]  Jacob Geday,et al.  PET neuroimaging of clomipramine challenge in humans: focus on the thalamus , 2001, Brain Research.

[32]  L. D. van de Kar,et al.  A desensitization of hypothalamic 5-HT1A receptors by repeated injections of paroxetine: reduction in the levels of G(i) and G(o) proteins and neuroendocrine responses, but not in the density of 5-HT1A receptors. , 1997, The Journal of pharmacology and experimental therapeutics.

[33]  P. Tonin,et al.  Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy. , 1996, Stroke.

[34]  P. Duncan,et al.  Defining post-stroke recovery: implications for design and interpretation of drug trials , 2000, Neuropharmacology.

[35]  T. Zetterström,et al.  Bi-phasic change in BDNF gene expression following antidepressant drug treatment , 2003, Neuropharmacology.

[36]  M. Torrens Co-Planar Stereotaxic Atlas of the Human Brain—3-Dimensional Proportional System: An Approach to Cerebral Imaging, J. Talairach, P. Tournoux. Georg Thieme Verlag, New York (1988), 122 pp., 130 figs. DM 268 , 1990 .

[37]  F. Artigas,et al.  Role of 5‐HT1A autoreceptors in the mechanism of action of serotoninergic antidepressant drugs: recent findings from in vivo microdialysis studies , 1996, Fundamental & clinical pharmacology.

[38]  B. Leventhal,et al.  Fenfluramine and cerebral glucose , 1992, Biological Psychiatry.

[39]  Q. Gu,et al.  Neuromodulatory transmitter systems in the cortex and their role in cortical plasticity , 2002, Neuroscience.

[40]  H. Okazawa,et al.  Reduction in serotonin synthesis following acute and chronic treatments with paroxetine, a selective serotonin reuptake inhibitor, in rat brain: an autoradiographic study with alpha-[14C]methyl-L-tryptophan(2). , 2001, Biochemical pharmacology.

[41]  Thomas E. Nichols,et al.  Positron Emission Tomographic Imaging of Serotonin Activation Effects on Prefrontal Cortex in Healthy Volunteers , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[42]  F. Chollet,et al.  Fluoxetine modulates motor performance and cerebral activation of patients recovering from stroke , 2001, Annals of neurology.

[43]  David J Gladstone,et al.  Toward Wisdom From Failure: Lessons From Neuroprotective Stroke Trials and New Therapeutic Directions , 2002, Stroke.

[44]  I. Hindmarch,et al.  The effects of paroxetine, alone and in combination with alcohol on psychomotor performance and cognitive function in the elderly , 1992, International clinical psychopharmacology.

[45]  O. Blin,et al.  Serotonin and human information processing: fluvoxamine can improve reaction time performance , 1997, Neuroscience Letters.

[46]  M. Diksic,et al.  Influence of Fluoxetine on Regional Serotonin Synthesis in the Rat Brain , 1996, Journal of neurochemistry.

[47]  François Chollet,et al.  Selective serotonin reuptake inhibitor paroxetine modulates motor behavior through practice. A double-blind, placebo-controlled, multi-dose study in healthy subjects , 2002, Neuropsychologia.

[48]  B. Saletu,et al.  Drug profiling by computed electroencephalography and brain maps, with special consideration of sertraline and its psychometric effects. , 1988, The Journal of clinical psychiatry.

[49]  D. Glanzman Postsynaptic regulation of the development and long-term plasticity of Aplysia sensorimotor synapses in cell culture. , 1994, Journal of neurobiology.

[50]  Trevor Sharp,et al.  A review of central 5-HT receptors and their function , 1999, Neuropharmacology.

[51]  P. Goldman-Rakic,et al.  Serotonergic axons in monkey prefrontal cerebral cortex synapse predominantly on interneurons as demonstrated by serial section electron microscopy , 1996, The Journal of comparative neurology.

[52]  M. Herrero,et al.  Functional anatomy of thalamus and basal ganglia , 2002, Child’s Nervous System.

[53]  O. Blin,et al.  Serotonin and human information processing: an electromyographic study of the effects of fluvoxamine on choice reaction time , 1999, Neuroscience Letters.

[54]  M. Geyer Serotonergic functions in arousal and motor activity , 1995, Behavioural Brain Research.

[55]  François Chollet,et al.  Correlation between cerebral reorganization and motor recovery after subcortical infarcts , 2003, NeuroImage.

[56]  François Chollet,et al.  Cerebral Functional Magnetic Resonance Imaging Activation Modulated by a Single Dose of the Monoamine Neurotransmission Enhancers Fluoxetine and Fenozolone during Hand Sensorimotor Tasks , 1999, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[57]  M Slifstein,et al.  In vivo quantification of brain serotonin transporters in humans using [11C]McN 5652. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[58]  R. C. Oldfield The assessment and analysis of handedness: the Edinburgh inventory. , 1971, Neuropsychologia.

[59]  Sylvain Houle,et al.  Neuromodulation of frontal and temporal cortex by intravenous d-fenfluramine: an [15O]H2O PET study in humans , 1996, Neuroscience Letters.